41
Participants
Start Date
April 8, 2019
Primary Completion Date
May 31, 2024
Study Completion Date
February 28, 2025
HQP1351
40 mg tablet, taken orally once every other day of a 28-day cycle
Peking University People's Hospital, Beijing
Union Hospital medical college Huazhong University of Science and Technology, Wuhan
Nanfang Hospital of Southern Medical University, Guanzhou
Shenzhen Second People's Hospital, Shenzhen
Sun Yat-sen University Cancer Center, Guangzhou
Henan Tumor Hospital, Zhengzhou
Tongji medical college Huazhong University of Science and Technology, Wuhan
The First Hospital Affiliated of Soochow University, Suzhou
West China Hospital of Sichuan University, Chengdu
Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin
Lead Sponsor
Ascentage Pharma Group Inc.
INDUSTRY